Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Basit Öğe Kaydı
dc.authorid0000-0002-7310-9328en_US
dc.authorid0000-0002-6291-7573en_US
dc.authorid0000-0001-7858-8180en_US
dc.contributor.authorKaraçin, Cengiz
dc.contributor.authorÖksüzoğlu, Berna
dc.contributor.authorDemirci, Ayşe
dc.contributor.authorBaytemür, Naziyet Köse
dc.contributor.authorYılmaz, Funda
dc.contributor.authorKalkan, Ziya
dc.contributor.authorKeskinkılıç, Merve
dc.date.accessioned2023-08-09T08:39:25Z
dc.date.available2023-08-09T08:39:25Z
dc.date.issued2023en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalıen_US
dc.description.abstractBackground There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the efectiveness of systemic treatments after CDKi and whether there is a survival diference between hormonal treatments (monotherapy vs. mTOR-based). Methods A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in frst-line (group A, n:202), second-line (group B, n: 153) and≥3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of group A, and 5.3 (3.9–6.8) months in the CT arm (p=0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and 5.7 (4.6–6.7) months in the CT arm (p=0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6) months in the CT arm (p=0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p=0.047), 6.7 vs. 5.0 (p=0.164), 6.7 vs. 3.9 (p=0.763) months. Conclusion Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as efective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after frst-line CDKi compared to monotherapy ET.en_US
dc.identifier.citationKaraçin, C., Öksüzoğlu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F. ve diğerleri. (2023). Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy. BMC Cancer, 23(1), 1-10.en_US
dc.identifier.doi10.1186/s12885-023-10609-8
dc.identifier.endpage10en_US
dc.identifier.issn1471-2407
dc.identifier.issue1en_US
dc.identifier.pmid36765293
dc.identifier.scopus2-s2.0-85147894207
dc.identifier.scopusqualityQ2
dc.identifier.startpage1en_US
dc.identifier.uriEfficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
dc.identifier.urihttps://hdl.handle.net/11468/12457
dc.identifier.volume23en_US
dc.identifier.wosWOS:000980043700010
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKalkan, Ziya
dc.language.isoenen_US
dc.publisherBioMed Central Ltden_US
dc.relation.ispartofBMC Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdvanced breast canceren_US
dc.subjectCyclin-dependent kinaseen_US
dc.subjectRibocicliben_US
dc.subjectPalbocicliben_US
dc.subjectEverolimusen_US
dc.subjectFulvestranten_US
dc.subjectEndocrine treatmenten_US
dc.subjectHormonotherapyen_US
dc.titleEfficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapyen_US
dc.titleEfficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under.pdf
Boyut:
1.52 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu